Indivior Model Projects 747 Staff Hour Cuts and $22,148 Monthly Savings in Prisons
Indivior's cost impact model estimates monthly injections of SUBLOCADE could cut staff hours by 318 versus methadone, 747 versus oral buprenorphine, 192 versus weekly buprenorphine and six versus extended-release naltrexone per 100 incarcerated patients. These reductions translate into monthly savings between $23 and $22,148 in correctional facilities.
1. Cost Impact Model Overview
Indivior released a cost impact model evaluating monthly injectable buprenorphine (SUBLOCADE) for treating opioid use disorder among incarcerated patients. The model compared staff time and costs across four MOUD options for a cohort of 100 prisoners each month.
2. Staff Time Reductions
The analysis found SUBLOCADE required 318 fewer staff hours than methadone, 747 fewer than oral buprenorphine, 192 fewer than weekly extended-release buprenorphine and six fewer than extended-release naltrexone for medication administration and patient monitoring.
3. Cost Savings Estimates
Reduced staff involvement produced estimated monthly cost savings ranging from $23 to $22,148, with the largest savings achieved by eliminating daily observed dosing and patient escort requirements in correctional settings.
4. Operational and Financial Implications
These findings indicate potential operational efficiencies for jails and prisons and a growth opportunity for Indivior as facilities seek to lower staffing burdens while expanding access to evidence-based treatments.